We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Part of massachusetts mutual life insurance co.
Clinical Trials
0
0 active
Approvals
33
Total approvals
Agencies
1
Regulatory bodies
Founded
2007
No trial phase data available
No trial data available
FDA
Food and Drug Administration
- GEn1E Lifesciences, a Phase 2 clinical-stage biotech company, has partnered with Rubicon Research to combine AI-powered patient endotyping with manufacturing and commercialization capabilities. - The collaboration will leverage GEn1E's proprietary GRID AI platform to enable precise patient stratification across Rubicon's portfolio, including central nervous system programs. - GEn1E's lead program, a host-directed small-molecule dual-signal modulator, has advanced from discovery to Phase 2 in approximately 2.5 years and received FDA Fast Track designation. - The partnership aims to enhance scalability and capital efficiency while expanding access to targeted therapies for patients with high unmet medical needs.
